Professional Documents
Culture Documents
Docx
Docx
Docx
Sigma Corporation is evaluating a project whose expected cash flows are as follows:
Year Cash flow (Rs.in million)
1 - 16.0
2 3.2
3 4.5
4 7.0
5 8.4
0.770
=
5
Try 14%
NPV = -16 + 3.2 (0.877) + 4.5 (0.769) + 7 (0.675) + 8.4 (0.592)
= -16 + 2.8064 + 3.4605 + 4.725 + 4.9728
= -0.0353
As this is very nearly zero, the IRR of the project is 14 %
(iii) What is the NPV * of the project if the reinvestment rate is 16%?
Solution:
Terminal
Value = 3.2 (1.16)3 + 4.5 (1.16)2 + 7 (1.16)1 + 8.4
= 3.2 (1.561) + 4.5 (1.346) + 7 (1.16) + 8.4
= 4.9952 + 6.057 + 8.12 + 8.4
= 27.5722
NPV* = 27.5722 - 16 = 1.5359
(1.12)4
Solution:
16 ( 1 + 1RR*)4 = 27.5722
27.5722
( 1 + 1RR*)4 = = 1.7233
16
1RR* = (1.7233) 1/4 -1
= 1.1457 - 1 = 14.57 %
Calculate the benefit cost ratio of this investment, if the discount rate is 12 percent.
Solution:
Calculate the benefit cost ratio of this investment, if the discount rate is 18 percent.
Solution:
By extrapolation,
Project B
By extrapolation,
r’’ =16 + (4.344-4.286)/(4.344- 4.207) = 16.42 %
5. Your company is considering two projects, M and N. Each of which requires an initial
outlay of Rs.240 million. The expected cash inflows from these projects are:
Solution:
Project M
The pay back period of the project lies between 2 and 3 years. Interpolating in
this range we get an approximate pay back period of 2.19 years.
Project N
The pay back period lies between 2 and 3 years. Interpolating in this range we
get an approximate pay back period of 2.25 years.
(b)
Project M
Cost of capital = 15 % p.a
Discounted pay back period (DPB) lies between 2 and 3 years. Interpolating in this range
we get an approximate DPB of 2.64 years.
Project N
Discounted pay back period (DPB) lies between 2 and 3 years. Interpolating in this range
we get an approximate DPB of 2.89 years.
(c ) Project M
Cost of capital = 15% per annum
NPV = - 240 + 85 x PVIF (15,1)
+ 120 x PVIF (15,2) + 180 x PVIF (15,3)
+ 100 x PVIF (15,4)
= - 240 + 85 x 0.870+120 x 0.756 + 180 x0.658
+ 100 x 0.572
= Rs. 100.31million
Project N
Cost of capital = 12% per annum
NPV = - 240 + 100 x PVIF (15,1)
+ 110 x PVIF (15,2) + 120 x PVIF (15,3)
+ 90 x PVIF (15,4)
=- 240 + 100 x0.870+ 110 x 0.756 + 120 x 0.658
+ 90 x 0.572
= Rs. 60.6 million
Since the two projects are independent and the NPV of each project is positive,
both the projects can be accepted. This assumes that there is no capital constraint.
(d) Project M
Cost of capital = 12% per annum
NPV = Rs.123.23 million
Project N
Cost of capital = 10% per annum
NPV = Rs.79.59 million
Since the two projects are mutually exclusive, we need to choose the project with the
higher NPV i.e., choose project M.
NOTE: The MIRR can also be used as a criterion of merit for choosing between the two
projects because their initial outlays are equal.
(e) Project M
Project N
Cost of capital: 15% per annum
NPV = Rs.32.57 million
Again the two projects are mutually exclusive. So we choose the project with the
higher NPV, i.e., choose project M.
(f) Project M
Project N
a. Cash flows from the point of all investors (which is also called the explicit cost funds point
of view).
b. Cash flows from the point of equity investors.
Solution:
Cash Flows from the Point of all Investors
Item 0 1 2 3 4 5 6
13. Net cash flow (200) (300) 187.5 180 174.4 170.2 367
Cash Flows from the Point of Equity Investors
Item 0 1 2 3 4 5 6
17. Net cash flow (200) - 159.5 103.2 102.5 103.2 204.9
7. Max Drugs Limited is a leader in the bulk drug industry. It manufactures a range of bulk
drugs, technically called APIs (active pharmaceutical ingredients). Max is considering a
new bulk drug called MBD-9.
You have recently joined Max as a finance officer and you report to Prakash Singh, Vice
President (Finance), who coordinates the capital budgeting activity. You have been asked to
develop the financials for MBD-9.
After discussing with marketing, technical, and other personnel, you have gathered the
following information.
The MBD-9 project has an economic life of 5 years. It would generate a revenue of Rs.50
million in year1 which will rise by Rs.10 million per year for the following two years.
Thereafter, revenues will decline by Rs.10 million per year for the remaining two years.
Operating costs (costs before depreciation, interest, and taxes) will be 60 percent of revenues.
MBD-9 is expected to erode the revenues of an existing bulk drug. Due to this erosion there will
be a loss of Rs.4 million per year by way of contribution margin for 5 years. While there
may be some other impacts as well, they may be ignored in the present analysis.
MBD-9 will require an outlay of Rs.40 million in plant and machinery right in the
beginning. The same will be financed by equity and term loan in equal proportions. The term
loan will carry an interest of 8 percent per annum and will be repayable in 4 equal annual
instalments, the first instalment falling due at the end of year 1.
For tax purposes, the depreciation rate will be 15 percent as per the written down value
method. The net salvage value of plant and machinery after 5 years is expected to be Rs.20
million.
The net working capital requirement will be 20 percent of revenues. Assume that the
investment in net working capital will be made right in the beginning of each year and the same
will be fully financed by working capital advance carrying an interest rate of 10 percent per
annum. At the end of 5 years the working capital is expected to be liquidated at par. The effective
tax rate is 30%
Required
1. Estimate the net cash flows relating to explicit cost funds (investor claims) over the 5-
year period.
2. Estimate the net cash flows relating to equity over the 5-year period.
Solution: